M&A and growth strongly feature -
Day 1 and 2 coverage of The 43rd annual JP Morgan Healthcare Conference with companies in the diagnostics and genomics tools markets providing updates on their businesses and previewing what may be coming down the pike. |
Thanks for the heads-up Simon.
Good to hear that someone else agrees that the strong dollar is good for EKF! And as you state, lots of cash being generated.
Interview with Chris Mills here (EKF 16min 40secs in) Interestingly, margins in the new enzyme facility are very high (which most of us knew), but Chis Mills describes the opportunity as being transformational for EKF, but which is subject to more effort and getting it right - |
STK MOVING |
For those interested, and to add to what is, hopefully, generally indicating a positive outcome for 2024 and a progressively positive continuation in 2025, the following presentations (ahead of their corporate results) from the 43rd Annual J.P. Morgan Healthcare Conference for Cardinal Health & Thermo Fisher, both of which are distributors of EKF products. EKF also have white label product agreements with both Cardinal and Thermo - |
Good update from Chris Mills on Vox this morning. Generating loads of cash, holding 15 million currently. Enzyme still slow but sounds like they are short of sales staff which is being addressed. No mention of dividend yet. Maybe to come in update. |
Positive preliminary earnings being reported for F/Y 2024 from a range of diagnostic players (with final results and more to follow in the coming weeks). Along with an interesting and positive backdrop for 2025 in life sciences, where apparently there is significantly improved balance sheets and opportunities across the sector, all of which will hopefully bode well for the areas EKF operate in. |
Nothing to do with it imho.
The long end of borrowing cost is heading upwards and will drain money from markets.
Potential for a reckoning if they creep higher - not good overall - way beyond Trumps mouth. Look at UK 30 yr yesterday - highest since 1998! Go figure. Will stuff hit the fan? One day. Might be sooner than expected. |
And then Donald opens his big mouth! |
Youd think EKF might also benefit from their small interests left in Vrci (up 100% over xmas) and Renx (up 80%). Guess they will catch on eventually. |
Big trade gone through. 987,692 at 26.6p ! |
They have been working to "right" the business. Taking a while. |
This share is highly illiquid and there has been precious little positive news for years - unfortunately. I don’t think that there is much/any benefit in tracking recent share trades. Unless and until the company can demonstrate that the business has recovered from entirely self—inflicted damage, the share price will remain depressed.Management has performed very poorly post pandemic. |
Crazy spread. 1k buy and share price jumps 7 percent. Ah only just seen the other trades. Some more hefty sells. Could the 40k been a buy? Not sure . A bit inbetween. Dont think we can consider this a change just yet |
What has become apparent again today is gross manipulation of the share price. 400,000 buy trades v 1bot trade of £25 and the share price drops 4 per cent! |
Now it drops 3.2 percent on the sale of two shares! One could say there is gross market manipulation, but who cares? Certainly not the regulators. Someone has bought 2k shares over 25.5p not enough to redress the 48 p trade! |
It will be interesting to see if the current improvement in the share price proves to be, eventually, a turning point in terms of a long-term upward trend...only more time will tell! |
A 1 million trade worked through the system today. Maybe that’s been the blockage as the share price back over 25p. Has been disappointing. Good interview with JB at Renx on Vox. Hopefully no more dilution there. share price not reacted that much but then the directors purchases have looked a bit token. Fingers crossed their diagnostics is selling very strongly according to Julian and should be welcomed by the incoming government |
Now would be a great time for the Directors to buy a shed load and show the market there is value to be had here....I have a view that back to 30p is the short term goal and 35p min.If they get things all lined up, 45p upwards in 12 months I don't think is a stretch.. although right now it looks it. |
It's certainly looking ripe for a hostile bid right now isn't it. My own view... too many delays and poor management in the past are all drags on the share price.Again, whilst we see potential, the market wants to see the money.. as do I.. |
That last flurry of sells reduced EKF's shares to a price to sales ratio of barely 2, compared to notably higher multiples in the sectors that EKF operates in. And under 2 if the broker forecast for 2025 is anywhere near correct.
A 40% bid at these prices would still only value EKF at well under 3 x, compared to higher average multiples in the diagnostics/healthcare sector etc, and again if the broker forecast is anywhere near correct!
One assumes that the market knows something that we currently don't! |
Smithie...What don't you understand about the post, particularly if you only considered the last two paragraphs? And especially if you follow and read the EKF link, but in short, BHB testing could become a materially larger market! -
Aside from the potential for therapeutics related to BHB: it has been identified in the above, and elsewhere, that there is a clear connection between ketosis and clearance of AD plaque, and indeed other benefits reported elsewhere related to the state of ketosis.
So, in my view there is likely to be a requirement for monitoring ketosis (including during clinical trials). EKF is well placed as they are already providing and addressing the need for the diagnosis and monitoring of patients with ketosis (and a potential future version currently in feasibility work-up). |
The half year report (September) showed marginal improvement and a cautious "in line" declaration.One trigger would be a "substantially in front of expectations " but the life sciences progress is steady (in my mind) not spectacular.On a plus side, higher gross profit from a slightly lower turnover can't be that bad and does bode well, indicating an eye to the numbers is evident.This is one of my bigger holdings. Had it not have been so big, I would have picked up more at this 25p level with an eye for a quick 20% profit. |
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Hot Features
Premium
